The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Magellan Financial Group (MFG) tumbles nearly 10 per cent on market after its funds under management fall by nearly $5 billion dollars in just a month
  • Funds under management dropped from $50.2 billion to $45.3 billion from November to December last year 
  • Significantly, for the six months to December, funds under management dropped by $58.9 billion from the corresponding period in 2021
  • Last month, Magellan’s net outflows were $2.6 billion, but it reported its performance fees – which fluctuate from period to period – were “not meaningful”
  • Shares in Magellan were trading down 9.07 per cent at $8.82 at 12:55 pm AEDT

Magellan Financial Group (MFG) has tumbled nearly 10 per cent on market today after it announced its funds under management fell by nearly $5 billion dollars in just a month, from November to December last year.

Total funds under management dropped from $50.2 billion to $45.3 billion.

Of that, retail funds were down from $20.6 billion to $18.9 billion, and institutional funds were down from $29.6 billion to $26.4 billion.

Significantly, for the six months to December, funds under management dropped by $58.9 billion from the corresponding period in 2021.

The greatest value drop was in global equities, down $4 billion. Investments in infrastructure equities and Australian equities also dipped.

Last month, Magellan’s net outflows were $2.6 billion, but it reported its performance fees – which fluctuate from period to period – were “not meaningful”.

Magellan funds will pay distributions, net of reinvestment, of approximately $0.3 billion this month.

Shares in Magellan were trading down 9.07 per cent at $8.82 at 12:55 pm AEDT.

MFG by the numbers
More From The Market Online
Rio de Janeiro

Equinox finds shallow and high-grade titanium ahead of MRE for Brazilian play

Equinox Resources Ltd has picked up a suite of strong results in titanium oxide and total…
Singapore skyline

Firebrick Pharma launching retail Nasodine sales in Singapore

Firebrick Pharma (ASX:FRE) has inked a deal with Guardian, a pharmacy chain in Singapore, to launch…
FDA HQ

Neurotech bounces back from FDA rejection with new NTI164 baseline study

Neurotech (ASX:NTI) has bounced back from a recent fast-track status rejection from the FDA, now launching…
Vietnam flag

TruScreen Group launches five-year cervical screening program in Ho Chi Minh City

TruScreen Group (ASX:TRU) has opted to launch a five-year cervical cancer screening run in Vietnam's Ho…